Fusion Antibodies plc, a Belfast-based biotech firm specializing in pre-clinical antibody discovery and therapeutic development, reported fiscal 2026 results showing a significant improvement in gross margin and operational efficiency. The company’s audited revenues rose to £2.1 million from £1.97 million in the prior year, with underlying service revenue reaching £1.86 million. Revenue in the second half of the fiscal year increased by 21% compared with the first half, reflecting steady commercial momentum.
Gross margin surged to 58.3%—up from 22% in fiscal 2025—after an amended announcement corrected an earlier misstatement of 53%. Operating loss improved to £1.13 million from a restated £1.63 million in the prior year. The company also recognized £872,000 in other operating revenue, largely from grants under its Future Medicines Institute program.
Commercialization efforts advanced with the launch of Fusion Antibodies’ OptiMAL platform in December 2025, following validation with the U.S. National Cancer Institute. Post-period, the company secured patent protection grants for OptiMAL in Japan and Canada, alongside regulatory acceptance in Australia. In January 2026, it raised approximately £1.4 million before expenses to support commercialization and working capital needs. As of March 31, 2026, the cash position stood at £1.04 million, up from £360,000 a year earlier.
The company continues to advance a grant-funded therapeutic antibody program, DR5, in collaboration with Queen’s University Belfast. Fusion Antibodies operates in the pre-clinical antibody discovery and supply space, targeting therapeutic and diagnostic applications.
